Skip to main content
. 2021 Nov 16;12:6624. doi: 10.1038/s41467-021-26912-6

Fig. 2. Protective efficacy of 1D8 against lethal EBV challenge in humanized mice.

Fig. 2

a Timeline for engrafting CD34 + human hematopoietic stem cells (HSC), antibody administration, viral challenge, and monitoring for various biological and clinical outcomes. 400 μg of 1D8 (n = 7), positive control AMMO1 (n = 8), negative control 2G4 (n = 7), or PBS (n = 8) were administered to the humanized mice via intraperitoneal injection either 24 h prior to or weekly for 5 weeks after intravenous challenge with Akata EBV. b EBV DNA in the peripheral blood, (c) body weight, and (d) survival were monitored weekly. The percent changes in (e) hCD45 + , (f) hCD20 + , or (g) hCD3+ cells over the experiment period. On week 6 post infection, (h) virus titers in spleen, (i) liver, (j) kidney were analyzed. All data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, no significant, two-tailed unpaired Student’s t test. (b) 1D8 vs PBS in 4w *p = 0.017, AMMO1 vs PBS in 4w *p = 0.010, ***p < 0.0001; (c) ***p < 0.0001; (d) 1D8 vs PBS ***p = 0.0002, AMMO1 vs PBS ***p = 0.0004, log-rank test (Mantel-Cox); (f) 1D8 vs PBS in 4w ***p = 0.0003, AMMO1 vs PBS in 4w **p = 0.0021, AMMO1 vs PBS in 5w **p = 0.001; (g) 1D8 vs PBS in 4w **p = 0.0028, AMMO1 vs PBS in 5w **p = 0.0034; (h) ***p < 0.0001, **p = 0.0048; (i) *p = 0.0126, **p = 0.008; (j) 1D8 vs PBS **p = 0.0052, AMMO1 vs PBS **p = 0.0013. Source data are provided as a Source Data File.